Sep 1, 2026
Longitudinal Assessment of Circulating Tumor Cells Expressing PD-L1 and Clusters in Esophageal Cancer Patients
A longitudinal study of 110 esophageal cancer patients evaluated CTCs, PD-L1 expression, and CTC clusters, highlighting their potential as predictive biomarkers for treatment outcomes and occult minimal cellular residual disease.
Aug 30, 2026
Detection of Androgen Receptor Splice Variant 7 in Circulating Tumor Cells for Dynamic Treatment Decision in Prostate Cancer Patients
This study evaluated AR-V7 in CTCs and clusters from prostate cancer patients, highlighting its potential to predict ARSI resistance and support dynamic treatment decisions.
Aug 30, 2026
Capture of Epithelial-Mesenchymal Transitioning Circulating Tumor Cells using Affinity Based N-Cadherin System
A study demonstrating N-Cadherin affinity-based capture of EMT-associated CTCs in diverse cancers, with Vimentin-positive CTC detection in 90% of samples and N-Cadherin expression revealing heterogeneous metastatic phenotypes.
Aug 30, 2026
Assessment of apprehension for Minimal Cellular Residual Disease Using Circulating Tumour Cells in Pre and Post Surgery Breast Cancer Patients
A prospective study evaluates RUPIKA, a structured CTC-based MRD disclosure protocol, showing significantly reduced cancer worry among breast cancer patients after surgery compared with routine result communication.
Aug 30, 2026
Capture of Cancerous Cells and Overall Survival in Rats using Ex-vivo Extracorporeal Device in Multiple Onco-dialysis Cycles
An animal study evaluated OncoMetastat for ex-vivo cancer cell capture, safety, and survival in rats. Across multiple onco-dialysis cycles, cancer cells were captured, all test-group rats survived 14 days, and histopathology showed normal tissues.
Aug 30, 2026
Comparative Analysis of Circulating Tumor Cells, Clusters, and PD-L1 Expression in Paired Peripheral and Portal Venous Blood with Solid Malignancies
A prospective study compares circulating tumor cells, CTC clusters, and PD-L1 expression in paired peripheral and portal venous blood, highlighting compartment-specific differences and the potential of dual-compartment liquid biopsy profiling.
Aug 30, 2026
Evaluation of circulating tumor cells expressing PD-L1 and CTC clusters at baseline and follow ups in triple-negative breast cancer
A retrospective study of 180 TNBC blood samples evaluated CTC burden, PD-L1 expression and CTC clusters using the CDSCO-approved OncoDiscover platform, highlighting their potential for longitudinal disease monitoring and biomarker-guided management.
Mar 17, 2026
ASCO 2026 : Association of circulating tumor cells with PD-L1 expression and clusters in confirmative tumor thrombus in selective solid cancers.
Study shows circulating tumor cells with PD-L1 expression in tumor thrombus patients, indicating active dissemination and potential metastatic risk.
Mar 17, 2026
ASCO 2026: Comparative enumeration of circulating tumor cells with PD-L1 over expression using anti EpCAM antibody to N-Cadherin in solid cancers
Dual EpCAM and N-cadherin profiling improves circulating tumor cell detection, enhancing minimal residual disease surveillance and identifying metastasis-prone cells.
Mar 17, 2026
ASCO 2026: Continual depletion of circulating tumor cells using an automated device enriched with affinity glass bead substrates in breast and CRC patient's whole blood.
Automated OncoMetastat device captures and depletes CTCs in colorectal and breast cancer, aiding detection of minimal residual disease and metastasis risk.
Mar 14, 2026
Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control
Actorius Innovations and Research Pvt Ltd, a pioneering Indo-US biotechnology company revolutionizing oncology through advanced circulating tumor cell (CTC) technologies, continues to make significant strides under the visionary leadership of Dr. Jayant Khandare, Founder, Managing Director, and Chief Scientific Officer.
Jan 27, 2026
Manuscript: Real-Time Therapy Response Monitoring Using Surface Biomarkers on Circulating Tumor Cells
Circulating tumor cells (CTCs), cancer cells shed from primary tumors into the bloodstream, are emerging as dynamic, non-invasive biomarkers for real-time cancer monitoring, especially when tissue biopsies are inaccessible or inadequate...
Nov 3, 2025
PD-L1 over-expression on Circulating Tumor Cells in Endometrial Cancer Patients
Khandare J, Ghadyalpatil N, Raja T, Velukuru S, Jadhav V, Satape R, Shinde S, Ashturkar A, Dattatreya P, Vasudevan A
Actorius Innovations And Research, Pune, Maharashtra, India; Apollo Cancer Institute, Hyderabad, Telangana, India; Apollo Cancer Centre, Chennai, Tamil Nadu, India; Aster CMI Hospital, Bangaluru, Karnataka, India; Renova Soumya Cancer Center, Hyderabad, Telangana, India.
Nov 3, 2025
Automated Continual Flow Device to Deplete Circulating Tumor Cells using Spiral Cartridge Mediated by Antibody and Transferrin Glass Substrate
Automated OncoMetastat device captures and depletes circulating tumor cells from whole blood safely, supporting extracorporeal cancer therapy and monitoring.
Oct 20, 2025
Non-hemolytic compositions and methods of use for recovering disease-causing toxic constituents in the blood
A non-hemolytic adsorbent composition designed to isolate, quantify, and remove disease-causing toxic constituents from blood, supporting disease identification, monitoring, and therapeutic efficacy validation.
- Page 1